|
WO2021042204A1
|
|
Biomarkers for cd47 blockade therapy
|
|
WO2020181386A1
|
|
Fluorinated benzo[f]benzimidazol-4-9-dione ium derivatives and pharmaceutical compositions thereof and their use as survivin suppressants
|
|
WO2020107115A1
|
|
Biomarkers for cd47 blockade therapy
|
|
AU2019336345A1
|
|
CD47 blockade with parp inhibition for disease treatment
|
|
WO2020010451A1
|
|
Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
|
|
CA3093549A1
|
|
Improvements in cd47 blockade therapy by egfr antibody
|
|
CA3093603A1
|
|
Cd47 blockade therapy and cd38 antibody
|
|
WO2019084692A1
|
|
Cd47 blockade with radiation therapy
|
|
WO2019071351A1
|
|
Novel fluorinated 4-aryloxyquinazoline derivatives as egfr inhibitors useful for treating cancers
|
|
WO2019006548A1
|
|
Fluorinated 2,4-diaminopyrimidine compounds as mer tyrosine kinase (mertk) inhibitors and uses thereof
|
|
WO2018176132A1
|
|
Cd47 blockade therapy
|
|
WO2018081898A1
|
|
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
CA3042581A1
|
|
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
AU2017250029A1
|
|
Macrophage stimulation in CD47 blockade therapy
|
|
US2019016689A1
|
|
Novel fluorinated quinazoline derivatives as egfr inhibitors
|
|
US2018312480A1
|
|
Heterocycle derivatives and their use for the treatment of CNS disorders
|
|
WO2017070793A1
|
|
Novel fluorinated heterocycle derivatives and their uses as therapeutic agents
|
|
US2018334425A1
|
|
Fluorinated amide derivatives and their uses as therapeutic agents
|
|
US2016347792A1
|
|
Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
|
|
CA2974442A1
|
|
Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
|
